Welcome to our dedicated page for Intellia Therapeutics news (Ticker: NTLA), a resource for investors and traders seeking the latest updates and insights on Intellia Therapeutics stock.
Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a pioneering clinical-stage gene editing company dedicated to revolutionizing medicine through the use of CRISPR-based therapies. Founded in 2014 by Caribou Biosciences and Atlas Venture, along with leading scientists in the field, Intellia harnesses the potential of CRISPR/Cas9 technology to develop curative treatments for a variety of genetically defined diseases.
The company's core mission is to leverage CRISPR/Cas9—an innovative technology adapted from a natural cellular process that allows for precise and flexible gene editing. This technology enables the correction of specific DNA sequences within any organism, opening new frontiers in biomedical research and clinical interventions.
Intellia's portfolio includes both in vivo and ex vivo gene editing programs. The in vivo programs aim to edit disease-causing genes directly within the human body, targeting conditions such as ATTR amyloidosis, hereditary angioedema (HAE), and alpha-1 antitrypsin deficiency. Notable achievements include the interim results from their NTLA-2002 program for HAE, which showed a 95% reduction in monthly attack rates, with most patients remaining attack-free.
The ex vivo programs focus on engineering human cells outside the body to treat cancer and autoimmune diseases. These programs include collaborations with prominent companies like Regeneron and Novartis, which help advance their therapeutic pipeline.
Intellia's financial condition reflects its robust pipeline and strategic partnerships. The company recently reported strong enrollment progress in their pivotal Phase 3 MAGNITUDE trial for NTLA-2001 targeted at ATTR amyloidosis with cardiomyopathy. They have also formed a strategic collaboration with ReCode Therapeutics to develop treatments for cystic fibrosis, utilizing ReCode's Selective Organ Targeting (SORT) lipid nanoparticle delivery platform.
Committed to advancing the field of gene editing, Intellia continues to expand its CRISPR-based platform with novel editing and delivery technologies. The company remains at the forefront of a new era in medicine, as evidenced by its ongoing clinical trials and promising preliminary data.
For more detailed information and the latest updates, investors and stakeholders are encouraged to visit www.intelliatx.com and follow Intellia on Twitter @intelliatx.
Intellia Therapeutics (NASDAQ:NTLA) announced that new interim data from the ongoing Phase 1 study of nexiguran ziclumeran (nex-z) will be presented at the 2024 American Heart Association (AHA) Scientific Sessions in Chicago. Nex-z is an investigational in vivo CRISPR-based gene editing therapy designed as a single-dose treatment for transthyretin (ATTR) amyloidosis.
The presentation will include safety data, reduction in serum TTR, biomarkers of disease progression, and functional capacity data in patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM). Dr. Marianna Fontana from University College London will present the findings on November 16, 2024, as part of the Late-Breaking Science session.
Intellia is developing nex-z in collaboration with Regeneron as part of a multi-target discovery, development, and commercialization partnership.
Intellia Therapeutics (NASDAQ:NTLA) has announced that detailed results from the Phase 2 study of NTLA-2002, their investigational in vivo CRISPR-based gene editing therapy for hereditary angioedema (HAE), will be presented at the 2024 ACAAI Annual Scientific Meeting. The presentation, titled "Results From a Phase 2, Randomized, Placebo-Controlled Trial of CRISPR-Based Therapy NTLA-2002 for Hereditary Angioedema," will take place on October 26, 2024. This follows a previous positive topline announcement that the study met its primary and all secondary endpoints. Intellia will also host an investor webcast on October 28, 2024, to review the new data.
Intellia Therapeutics (NASDAQ:NTLA), a leading clinical-stage gene editing company, has announced inducement grants for five new employees under its 2024 Inducement Plan. The grants include:
- Non-qualified stock options for 49,751 shares
- Time-based RSUs for 44,154 shares
- Performance-based RSUs for 17,064 shares linked to total stockholder return
- Performance-based RSUs for 12,500 shares tied to development milestones
These equity awards, granted outside of Intellia's stockholder-approved plans, were approved by the compensation committee as a material inducement for employment, in accordance with Nasdaq Listing Rule 5635(c)(4).
Intellia Therapeutics (NASDAQ:NTLA) reported positive Phase 2 results for NTLA-2002 in hereditary angioedema (HAE), meeting primary and secondary endpoints. The company plans to initiate a Phase 3 trial in 2H 2024 with the selected 50 mg dose. Rapid enrollment continues in the Phase 3 MAGNITUDE trial of NTLA-2001 for ATTR amyloidosis with cardiomyopathy. Intellia expects to dose the first patient in the Phase 1/2 study of NTLA-3001 for alpha-1 antitrypsin deficiency in 2H 2024. The company ended Q2 2024 with $939.9 million in cash, expected to fund operations into late 2026. Q2 financial results show collaboration revenue of $7.0 million, R&D expenses of $114.2 million, and a net loss of $147.0 million.
Intellia Therapeutics (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on CRISPR-based therapies, has announced its upcoming second quarter 2024 earnings call. The conference call is scheduled for August 8, 2024, at 8 a.m. ET. During this call, the company will present its Q2 2024 financial results and provide operational highlights.
Investors and interested parties can join the call by dialing 1-833-316-0545 (U.S.) or 1-412-317-5726 (international). A live webcast will also be available. A replay of the call will be accessible through Intellia's website after 12 p.m. ET on the same day.
Intellia Therapeutics (NASDAQ:NTLA) has received authorization from the UK's MHRA to initiate a Phase 1/2 clinical trial for NTLA-3001, a potential one-time CRISPR-based gene editing treatment for alpha-1 antitrypsin deficiency (AATD)-associated lung disease. NTLA-3001 aims to normalize AAT protein levels by inserting a healthy copy of the SERPINA1 gene, potentially halting disease progression and eliminating the need for weekly infusions or lung transplants.
The study will enroll up to 30 adult patients and evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics. Intellia plans to dose the first patient in the second half of 2024. This trial marks Intellia's first wholly owned in vivo targeted gene insertion candidate to enter clinical stages, validating their modular gene insertion platform for addressing various protein deficiency diseases.
Intellia Therapeutics (NASDAQ:NTLA), a leading clinical-stage gene editing company, has announced inducement grants for its new Executive Vice President and Chief Financial Officer, Edward Dulac. The grants, awarded on July 22, 2024, include:
96,219 non-qualified stock options with an exercise price of $25.33 per share, vesting over three years; 66,324 time-based restricted stock units (RSUs) vesting annually over three years; 33,162 performance-based RSUs tied to total stockholder return over three years; and 30,000 performance-based RSUs (at target) linked to development milestones over three years.
These grants were made outside of Intellia's stockholder-approved equity incentive plans, under the 2024 Inducement Plan adopted in June 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).
Intellia Therapeutics (NASDAQ:NTLA) announced the appointment of Edward Dulac as the new Executive Vice President, Chief Financial Officer (CFO), and Treasurer, effective July 22, 2024. Dulac will replace Glenn Goddard, who steps down on June 30, 2024. Dulac brings over 20 years of experience in finance, business development, and corporate strategy from roles at Fate Therapeutics, Celgene (now Bristol Myers Squibb), Barclays Capital, Lehman Brothers, and Pfizer. Intellia's CEO, John Leonard, expressed confidence in Dulac's ability to drive the company's future commercial success and thanked Goddard for his contributions. This leadership transition marks a significant step as Intellia continues to advance its CRISPR-based therapies.
Intellia Therapeutics has announced positive clinical data demonstrating the potential for redosing with its proprietary CRISPR-based therapy, NTLA-2001. In a Phase 1 study, a follow-on 55 mg dose led to a 90% median reduction in serum TTR at day 28 among three patients who previously received the lowest dose. This redosing capability, enabled by Intellia's non-viral lipid nanoparticle (LNP) delivery platform, is not currently planned for the NTLA-2001 program but shows promise for future therapies requiring additive effects. The 55 mg follow-on dose was well tolerated, with only one mild infusion-related reaction reported. The NTLA-2001 program is part of a collaboration with Regeneron. The promising results will inform Phase 3 trials for ATTR-CM and ATTRv-PN.
Intellia Therapeutics (NASDAQ: NTLA) will present groundbreaking clinical data on redosing patients with its investigational CRISPR gene editing therapy, NTLA-2001, at the Peripheral Nerve Society Annual Meeting from June 22-25, 2024, in Montreal, Canada.
The Phase 1 study data, featuring redosing of three patients initially administered 0.1 mg/kg followed by a 55 mg dose, will provide insights into the safety and pharmacodynamics of this approach.
While repeat dosing is not planned for NTLA-2001 in treating transthyretin amyloidosis (ATTR), it could benefit future therapies using Intellia’s lipid nanoparticle (LNP) delivery platform by enabling additional dosing where needed.
Dr. Jorg Taubel will present these findings on June 25, 2024.
FAQ
What is the current stock price of Intellia Therapeutics (NTLA)?
What is the market cap of Intellia Therapeutics (NTLA)?
What is the mission of Intellia Therapeutics?
What diseases is Intellia targeting with their CRISPR-based therapies?
What are Intellia's key advancements in hereditary angioedema (HAE) treatment?
When was Intellia Therapeutics founded?
Who are Intellia's key collaborators?
What is CRISPR/Cas9?
How does Intellia's in vivo program work?
What are the recent financial highlights of Intellia Therapeutics?
What is the scope of Intellia's collaboration with ReCode Therapeutics?
Where can I find more information about Intellia Therapeutics?
